{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29","upperLimit":"72","value":"53"},{"groupId":"OG001","lowerLimit":"59","upperLimit":"95","value":"84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Estimates will be calculated using the Kaplan-Meier method, Greenwood formula will be used to calculate standard error (SE), and log-log transformation method will be used to construct 95% confidence intervals. Graft versus host disease (GVHD, acute and chronic), disease status and vital status will be monitored per clinical standard operating procedure. For this endpoint failure is defined as the first occurrence of grade 3 or 4 acute GVHD, or moderate/severe chronic GVHD, or disease relapse (for patients in complete remission at the start of conditioning) or disease progression (for patients with active disease at the start of conditioning) or death (from any cause). Patients not experiencing any of these will be censored at his/her date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMelphalan Hydrochloride: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV","id":"OG000","title":"Regimen A (Fludarabine, Melphalan, PBSC HCT, GVHD Prophylaxis)"},{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV\n\nTotal-Body Irradiation: Undergo TBI","id":"OG001","title":"Regimen C (Fludarabine, TBI, PBSC HCT, GVHD Prophylaxis)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From stem cell infusion to grade 3-4 acute graft versus host disease (GVHD), moderate-severe chronic GVHD, relapse, progression or death (from any cause), whichever occurs first, assessed for up to 1 year.","title":"Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) at 1 Year","type":"PRIMARY","unitOfMeasure":"percentage of survival probability"}